PhRMA Claims Transparency Risks Damaging Public Health

Publishing information from clinical trials “risks damaging public health and patient welfare” says the Pharmaceutical Research and Manufacturers of America. PhRMA made the statement in a letter to the chief US trade negotiator for the free trade agreement between the European Union and the USA, the Transatlantic Trade and Investment Partnership deal. In the letter, PhRMA says, “Disclosure of companies’ non-public data submitted in clinical and pre-clinical dossiers and patient-level data risks damaging public health and patient welfare.”